Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nektar Therapeutics - Common Stock (NQ:NKTR)

0.7520 +0.0020 (+0.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nektar Therapeutics - Common Stock

< Previous 1 2 3 4 5 Next >
What 4 Analyst Ratings Have To Say About Nektar Therapeutics
Analysts have provided the following ratings for Nektar Therapeutics (NASDAQ:NKTR) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
Via Benzinga
Where Nektar Therapeutics Stands With Analysts
Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022
Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the... 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Wells Fargo cut the price target on Coupa Software Incorporated (NYSE: LPI) from $190 to $80. Laredo Petroleum shares fell 29.8% to $63.10 in pre-market trading. 
Via Benzinga
Why is Nektar Therapeutics (NKTR) Stock Down Today?
Nektar Therapeutics is down big today after ending some of its clinical trials. What's going on with NKTR stock? 
Via InvestorPlace
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
96 Biggest Movers From Yesterday
Gainers Volt Information Sciences, Inc. (NYSE: VOLT) shares surged 94.7% to close at $5.88 on Monday after the company announced it would be acquired for $6 per share. Incannex... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap... 
Via Benzinga
Mid-Afternoon Market Update: Dow Turns Negative; Turquoise Hill Resources Shares Spike Higher
U.S. stocks turned lower toward the end of trading on Monday as the Dow Jones dropped 100 points, after surging more than 400 points earlier during the session. The Dow... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Incannex Healthcare (NASDAQ:IXHL) stock moved upwards by 48.0% to $20.95 during Monday's regular session. The company's market cap stands at $1.0 billion.... 
Via Benzinga
Knightscope News: Why Is KSCP Stock Up Today?
Knightscope (KSCP) stock is on the move Monday following news that the company signed onto a new real estate development project. 
Via InvestorPlace
Mid-Day Market Update: Markets Mixed; Nasdaq Drops Over 100 Points
The Nasdaq index turned lower midway through trading, losing more than 100 points on Monday. The Dow traded up 0.61% to 33,143.88 while the NASDAQ fell 1.13% to 12,698.26.... 
Via Benzinga
50 Stocks Moving In Monday's Mid-Day Session
Gainers Volt Information Sciences, Inc. (NYSE: VOLT) shares jumped 95.2% to $5.89 after the company announced it would be acquired for $6 per share. AgriFORCE Growing Systems,... 
Via Benzinga
Bristol Myers, Nektar Melanoma Doublet Therapy Trial Fails To Show Clinical Benefit
Bristol Myers Squibb Co (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) have an update following the first analysis of the Phase 3 PIVOT IO-001 study of... 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; Crude Oil Dips 8%
U.S. stocks opened on a strong note this morning, with the Dow Jones gaining 300 points on Monday. Following the market opening Monday, the Dow traded up 0.99% to 33,269.95 while... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2022
Upgrades Janney Montgomery Scott upgraded the previous rating for Enova International Inc (NYSE:ENVA) from Neutral to Buy. Enova International earned $1.61 in the fourth quarter,... 
Via Benzinga
Nektar Therapeutics Loses Half Its Value As Bristol Myers-Paired Melanoma Test Flops
Sentiment was low heading into the study and analysts aren't hopeful for other tests. 
Via Investor's Business Daily
Why Nektar Therapeutics Shares Are Falling Today
Nektar Therapeutics (NASDAQ: NKTR) is trading significantly lower Monday morning after the company's Phase 3 PIVOT trial, in combination with Bristol-Myers Squibb Co (... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Erytech Pharma (NASDAQ:ERYP) stock rose 18.7% to $1.65 during Monday's pre-market session. The market value of their outstanding shares is at $51.1 million.... 
Via Benzinga
Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma
From Bristol Myers Squibb
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2022
Upgrades Roth Capital upgraded the previous rating for Hudson Technologies Inc (NASDAQ:HDSN) from Neutral to Buy. For the fourth quarter, Hudson Technologies had an EPS of $0.13,... 
Via Benzinga
Nektar Therapeutics: Q4 Earnings Insights
Nektar Therapeutics (NASDAQ:NKTR) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
Earnings Outlook For Nektar Therapeutics
Nektar Therapeutics (NASDAQ:NKTR) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Big Trend Occurring in Triple-Negative Breast Cancer Treatment Is The Shift Towards Combination Therapy
Palm Beach, FL – December 10, 2021 – FinancialNewsMedia.com News Commentary – Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options... 
Via FinancialNewsMedia
7 Drug Stocks to Buy Now While They’re Still on Sale
Covid-19 stocks soared to unsustainable highs as investors ignored drug stocks with a deep pipeline of products for the decade ahead. 
Via InvestorPlace
Topics Supply Chain
Exposures COVID-19 Supply Chain
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021
Upgrades For Nektar Therapeutics (NASDAQ: 
Via Benzinga
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:... 
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
92 Biggest Movers From Friday
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.